drugset / Trial / NCT00772577

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

NCT00772577

Phase 4 Completed 386 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension

Timeline

Start
2008-08
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Hydrochlorothiazide Unknown 25 mg
Comparator Ramipril Small molecule 10 mg

Indications